Follow The Post’s investigation of the epidemic

Follow The Post’s investigation of the epidemic

Since 2016, The Washington Post has been investigating the opioid epidemic that has ravaged communities and claimed the lives of more than 400,000 people nationwide.

On July 16, The Post disclosed a previously unreleased Drug Enforcement Administration database that tracks the path of every pain pill sold in the United States. The disclosure is part of a civil action brought by 2,500 cities, towns, counties and tribal nations alleging that nearly two dozen drug companies conspired to saturate the nation with opioids. The database and additional court exhibits were made public after a legal challenge by The Post and the owner of the Charleston Gazette-Mail in West Virginia.

The Post made its findings accessible to journalists to download and use in their reporting. Journalists from over 35 states have published more than 129 articles based on the previously undisclosed DEA data.

Download the DEA data | How journalists are using the data

The database is a virtual road map to the epidemic. The exhibits, which include internal drug company emails and memos, regulatory records and other documents, reveal the business practices that gave rise to the opioid crisis.

Here are the major stories to understand the series:

1. America’s largest drug companies distributed billions of oxycodone and hydrocodone pain pills across the country. The Post initially learned 76 billion pills saturated the country between 2006 and 2012. Additional reporting revealed the breadth of distribution between 2006 and 2014: More than 100 billion pills. Just six companies distributed 76 percent of the pills during this period.

2. The volume of pills handled by the companies climbed as the epidemic surged, increasing 51 percent during a seven-year time frame. An interactive database of pain pill shipments shows the locations that were inundated with opioids.

3. Deaths from opioids soared in the communities that were flooded with pain pills. The highest per capita death rates nationwide were in rural West Virginia, Kentucky and Virginia.

4. Internal documents showed the pressure within drug companies to sell opioids in the face of numerous red flags. The exhibits reveal concerns by some drug company employees about the huge number of pain pills being distributed.

5. Records show that by 2006, as the number of overdose deaths grew, a handful of obscure generic-drug manufacturers were selling the bulk of opioid pills flooding the country.

6. Walgreens dominated the nation’s retail opioid market. The company handled nearly one in five of the most addictive opioids and acted as its own distributor.

Listen to Post Reports

‘We was addicted to their pill, but they was addicted to the money’

Norton, Va. was flooded with 306 pain pills per person per year from 2006 to 2012. Now, those devastated by the opioid crisis are demanding accountability.

Here are some other stories that tell the struggles of those affected by the crisis:

Over seven years, the database shows, drug companies shipped a combined 74 million opioid pills to the city of Norton, Va., and the three surrounding counties — enough for 106 pills per resident every year. (Charles Mostoller/for The Washington Post)

The battle in the courtroom

The fight over who is accountable for the epidemic has led to the largest civil case in U.S. history and involves nearly two dozen major drug companies. The 2,500 cases from around the nation have been consolidated in U.S. District Court in Cleveland. In October, several drug companies reached a $260 million settlement with two counties in Ohio. Johnson & Johnson, which owned two companies that processed and imported raw material to manufacture oxycodone, reached its own settlement. The remaining cases are pending.

Purdue Pharma, the drug manufacturer accused of triggering the nation’s epidemic through its sale of OxyContin, filed for bankruptcy in September.

Dig deeper into the drug industry

Throughout its reporting, The Post learned how drug company lobbyists allied with members of Congress to derail the DEA’s efforts to go after distributors. The Post further helped shed light on the drug industry’s efforts to lobby for a law that weakened one of the government’s most powerful drug enforcement tools.

In the middle of the epidemic, the drug industry used aggressive marketing practices to ramp up the sale of opioids. Watch how they made it happen in our documentary below.

Explore two other companies involved in the distribution and sale of pain pills: McKesson Corp., the nation’s largest drug company, and Mallinckrodt Pharmaceuticals, one of the nation’s largest manufacturers of oxycodone.

The Post’s coverage over the years


Frank Younker, a retired DEA supervisor in Cincinnati, said he had trouble getting cases approved during the opioid epidemic. (Matt McClain)

In early 2016, The Post began investigating how hundreds of millions of highly addictive pain pills that are sent along a tightly regulated pharmaceutical supply chain were fueling a growing, deadly epidemic.

Starting in 2006, the DEA launched an aggressive campaign to curb the rising opioid epidemic, targeting wholesale companies that distributed hundreds of millions of highly addictive pills and to the corrupt pharmacies and pill mills that illegally diverted the drugs to the black market. But the industry fought back, and soon officials at DEA headquarters were delaying and blocking enforcement actions.

Thirteen drug distributors knew or should have known that hundreds of millions of pills were ending up on the black market, according to court records, DEA documents and legal settlements in administrative ­cases reviewed by The Post. Even when the companies were alerted to suspicious pain clinics or pharmacies by the DEA and their own employees, some distributors ignored the warnings and continued to send drugs.

Pharmaceutical companies have hired dozens of officials from the top levels of the DEA during the past decade. The hires came after the DEA launched an aggressive campaign to curb the rising opioid epidemic.


In 2017, reporters dug deeper into the issue, working with “60 Minutes” to explore in greater depth the pressure that had been exerted on Congress by the drug industry and its lobbyists and its impact on some key DEA investigations into large drug companies.

At the height of the deadliest drug epidemic in U.S. history, Congress effectively stripped the DEA of its most potent weapon against large drug companies suspected of spilling prescription narcotics onto the nation’s streets. The law was the crowning achievement of a multifaceted campaign by the drug industry to weaken DEA enforcement efforts by working behind the scenes with lobbyists and key members of Congress.

After two years of painstaking investigation, a DEA team was ready to move on the biggest opioid distribution case in U.S. history. Instead, top attorneys at the DEA and the Justice Department struck a deal that was far more lenient than the field agents wanted, according to interviews and internal government documents.

In 2012, distributor Cardinal Health got word that the DEA was about to take action against a Florida warehouse that supplied millions of painkillers to customers every month. Cardinal retained one of Washington’s best-connected power lawyers, Jamie Gorelick, who had served as deputy U.S. attorney general from 1994 to 1997. She reached out to her old agency on the company’s behalf, and the impact was immediate.

2018 AND 2019

Inmates in the women’s cellblock at the Fayette County Jail in Washington Court House, Ohio, a state hit hard by the country’s fentanyl crisis. (Salwan Georges/The Washington Post)

In 2018 and 2019, The Post turned its focus to the synthetic painkiller fentanyl, the latest wave of the opioid crisis, which claimed the lives of about 30,000 that year. Pain pill addiction had given rise to heroin use, which in turn created a soaring demand for fentanyl, which is 50 times as powerful as heroin.

Federal officials failed to grasp how quickly fentanyl was creating another — and far more fatal — wave of the epidemic. In the span of a few short years, fentanyl became the drug scourge of our time. If current trends continue, the annual death toll from fentanyl will soon approach the yearly toll from guns or traffic accidents.

The depth of the fentanyl problem continues to overwhelm the government’s response, and the administration has yet to produce a comprehensive strategy that is legally required by Congress. Health policy experts say treatment funding is not nearly enough, and the Trump administration’s response was hobbled by the failure to appoint a drug czar in its chaotic first year and confusion over who was in charge of drug policy.

The flow of fentanyl into the United States from China was facilitated for years by the illicit use of the U.S. Postal Service and other persistent vulnerabilities at the nation’s ports of entry.

As deaths mounted from fentanyl overdoses, Congress took little action to address the epidemic or stop the flow of the deadly drug into the United States.

We noticed you’re blocking ads!

Keep supporting great journalism by turning off your ad blocker. Or purchase a subscription for unlimited access to real news you can count on.
Unblock ads
Questions about why you are seeing this? Contact us